Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 55.56 yuan, reflecting a 2.17% increase as of February 25, 2026, with significant trading activity and net inflows from major funds [1]. Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2]. - The net profit attributable to the parent company reached 260 million yuan, up 3.3% year-on-year, while the net profit after deducting non-recurring items was 222 million yuan, an increase of 1.46% [2]. - In Q3 2025 alone, the company achieved a quarterly revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2]. - The quarterly net profit attributable to the parent company was approximately 92.83 million yuan, reflecting a 38.68% increase year-on-year, and the net profit after deducting non-recurring items was about 85.80 million yuan, up 62.68% [2]. - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while the gross profit margin is reported at 53.35% [2]. Market Sentiment - Over the past 90 days, four institutions have rated Kefu Medical with a "buy" rating, indicating strong institutional confidence in the stock [3]. - The average target price set by institutions in the last 90 days is 53.84 yuan, suggesting a positive outlook for the stock [3].
股票行情快报：可孚医疗（301087）2月25日主力资金净买入905.77万元